Cognitio

In this BioBeacon edition of the Cognitio Podcast, ARCS CEO Tim Boyle speaks with Paul Batten, founder of ObjectivoData, about his unexpected journey from mechanical engineering and McLaren to clinical trial technology. Paul shares how working on a COVID-era telehealth trial exposed the need for more intuitive, flexible and user-centred clinical trial systems. That experience became the foundation...

What if you could give a stroke patient more time? That is the question driving Dr Daniel Beard and the team at ShearFlow, a biotech spin-out from the University of Newcastle developed in joint venture with Harvard University. In this episode, ARCS intern Iqra sits down with Daniel to trace a career that has taken him from a fascination with the brain's blood vessels, through a PhD in stroke r...

Artificial intelligence is already reshaping how regulatory professionals work—but with opportunity comes responsibility. In this episode of Cognitio, we bring you key insights from an ARCS webinar led by Kyle from GXP Vigilance, exploring how AI is being used across regulatory affairs, pharmacovigilance and quality environments, and what professionals need to understand to use it safely and effec...

This week on Top 3 with Tim, ARCS CEO Dr Tim Boyle shares the biggest updates shaping the ARCS community and Australia’s life sciences sector. In this short update: • Final call for 2026 ARCS Annual Conference early bird registrations • ARCS announces its new partnership with the Australian Institute of Company Directors (AICD) and the upcoming LifeSciences Company Directors Course • Highlights fr...

How do we separate misinformation from meaningful public health signals, and what happens when digital intelligence is combined with clinical evidence? In this episode of Cognitio, we explore how online sentiment, AI-powered surveillance and real-world healthcare data can work together to identify, investigate and validate emerging vaccine safety concerns. Dr Gerardo Luis Dimaguila, Informatics Le...

What does high performance really look like when it’s shaped by lived experience? In this episode of Cognitio , we explore the intersection between professional capability and chronic illness—and how navigating personal health challenges can fundamentally shape resilience, leadership, and perspective in the life sciences sector. Hosted by Anna Megalakakis from ARCS, this conversation brings togeth...

What can elite sport teach us about leadership in the workplace? In this episode of the Cognitio Podcast, Tim Boyle sits down with Tomek Szklarski, Head Coach of the Australian National Handball Team, to explore how high-performance sporting environments develop resilient leaders, build trust under pressure, and create cultures where teams thrive. Drawing on his experience as both a professional a...

What does it really mean to design healthcare with patients? In this episode of the Cognitio Podcast, Georghien Wiley, ARCS Convener for the Patient Engagement Interest Area, leads a powerful and deeply personal discussion on patient co-creation. Through real-world experiences, this episode explores the realities of navigating the healthcare system in Australia, particularly for patients and carer...

Cell and gene therapies such as CAR-T are transforming modern medicine, offering new treatment options for cancers and rare diseases. But getting these breakthrough therapies to patients is not straightforward. In this episode of the Cognitio Podcast, Warwick Shaw from Johnson & Johnson explores how advanced therapies move from regulatory approval to reimbursement in Australia. The discussion...

Three signals this week point to a sector at a turning point. Australia’s life sciences industry is accelerating—with stronger local capability, growing global engagement, and a more coordinated national R&D strategy taking shape. But there’s a critical question we need to address. As we move toward a more economically driven innovation model, how do we ensure health and medical research remai...

In this episode of Cognitio , Tim Boyle speaks with Dr Natalie Anderson about the evolving regulatory landscape for non-animal models in pharmaceutical development. We explore global reforms at the US FDA and European Medicines Agency, the application of the Three Rs, and how Australia’s TGA is responding to advances in organoids, organ-on-chip technologies and in silico modelling. The discussion...

In this episode of Cognitio , ARCS CEO Tim Boyle explores the behavioural science behind leadership, compliance and decision-making in regulated environments. Despite extensive training and detailed SOPs, deviations still occur. So what’s missing? This conversation dives into the psychology of identity-based leadership, the forgetting curve, grey zone decision-making, and how culture shapes compli...

What are the three biggest developments shaping Australia’s life sciences sector this week? In this short weekly briefing, ARCS CEO Tim Boyle shares the top stories from across the medicines, medical devices and clinical research ecosystem. This week’s episode covers: • A major step toward professional standards and competency-based accreditation for the clinical trials workforce following discuss...

What changes when a therapy moves from clinical trials to the real world? In this episode of the Cognitio podcast, ARCS Australia CEO Tim Boyle speaks with Carl Bufe about the critical differences between clinical development safety management and post-market pharmacovigilance. From SUSAR reporting and ICH E6 to ICH E2D, signal detection, spontaneous adverse event reporting and scaling safety syst...

This week in Australian life sciences: a $1.6B digital health acquisition, global momentum in cell and gene therapy, AI in regulatory affairs, and registrations opening for the 2026 ARCS Annual Conference. In this short episode, Tim Boyle breaks down the top 3 stories shaping biotech, medtech, clinical trials and therapeutic product commercialisation across Australia and the Asia-Pacific. Fast ins...

Cell and gene therapies are transforming medicine — from CAR-T in oncology to next-generation gene therapies targeting rare disease. Ahead of the ARCS–DIA Cell & Gene Therapy Summit, Tim Boyle and Anna Megalakakis unpack Australia’s advanced therapies landscape. They explore manufacturing capability, workforce shortages, funding reform, regulatory pathways, and whether Australia can scale beyo...

This week’s ARCS sector update covers three major developments shaping Australia’s medtech and pharmaceutical landscape. We unpack the AMR 2026 Summit in Sydney and the release of the Sixth AURA Report, highlighting why antimicrobial resistance is now an economic and national resilience issue. We examine the surge in PBS activity, with more than 20 medicines nearing listing decisions, and what thi...

South Korea has rapidly established itself as one of the world’s leading destinations for clinical research. With dense urban populations, advanced hospital infrastructure and a highly structured regulatory framework, it is now consistently ranked among the top countries globally for clinical trial activity. In this episode of the Cognitio Podcast, we explore what makes South Korea such a compelli...

Global recognition for the TGA. PBS tensions escalating into legal action. And major leadership shifts across pharma. In this episode, Tim Boyle breaks down the three biggest stories shaping Australia’s life sciences sector this week — and why they matter for regulatory affairs, market access, clinical research and pharma professionals. What does WHO recognition mean for the TGA’s global influence...

Advancing LGBTQIA+ Inclusion in Healthcare and Research In this episode of Cognitio , ARCS Australia CEO Tim Boyle explores why LGBTQIA+ inclusion is no longer optional in healthcare, clinical research, and the life sciences sector. Drawing on insights from an ARCS webinar featuring guests from Proud Science Alliance and ACON, this episode unpacks the real-world consequences of under-representatio...

A big week for policy, funding and medicine access. In this episiode, I break down my top three life sciences stories for the week and why they matter for Australia’s sector. ARCS members get the full weekly briefing via email. Join ARCS to stay across what matters.

🎙️ ARCS Weekly News Wrap — Final Episode of 2025 Tim and Anna team up for the final Weekly News Wrap of the year, bringing you the most significant stories shaping Australia’s life sciences landscape. This fast, engaging episode covers the biggest pharma leadership moves, biotech breakthroughs, rare disease reform, PBS milestones, digital health shake-ups, and major medtech developments — includin...

Inclusive clinical research is not a box to tick. It is a way of working. In this episode of the Cognitio Podcast, Tim Boyle is joined by webinar presenters Jane Gaunson, Olivia Payne, Mariam Hachem and Bernard Kelly-Edwards to explore practical strategies for partnering with Aboriginal and Torres Strait Islander communities in clinical research. The conversation highlights the role of the Victori...

In this week’s ARCS Weekly News Wrap, Tim Boyle unpacks the headlines shaping Australia’s medicines, medtech and biotech sectors, with a sharp eye on what they mean for professionals working across the product lifecycle. We cover key policy and reimbursement signals, regulatory and manufacturing developments, notable biotech and medtech milestones, and the people moves that hint at where the marke...

In this episode of the Cognitio Podcast, Tim Boyle introduces a powerful conversation on innovation, access, and equity in clinical trials. Featuring Julia Linda from Eli Lilly Australia and Melissa Reilly from Heart of Australia , the episode explores how clinical research can be delivered to regional, rural, and First Nations communities through innovative models and strong cross-sector partners...